CLEARVIEW PUBLISHING - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/185982.xml CLEARVIEW PUBLISHING - Press Releases en xml@emediawire.com xml@emediawire.com 30 New Antipsychotic Invega Offers Few Advantages, Poses Cardiac Risks, According to Company Studies http://www.prweb.com/releases/2007/03/prweb508352.htm The latest antipsychotic to be approved by the FDA, Janssen's Invega, offers few advantages over existing agents, and poses significant cardiac risks, according to a new analysis by The Carlat Psychiatry Report. (PRWeb Mar 6, 2007)

Read the full story at http://www.prweb.com/releases/2007/03/prweb508352.htm

]]> http://www.prweb.com/releases/2007/03/prweb508352.htm FDA Fails To Regulate Natural Treatments For Psychiatric Conditions http://www.prweb.com/releases/2006/04/prweb366478.htm Hundreds of “natural” treatments are marketed for psychiatric conditions but are essentially unregulated by the FDA, according to the April issue of The Carlat Psychiatry Report. (PRWeb Apr 2, 2006)

Read the full story at http://www.prweb.com/releases/2006/04/prweb366478.htm

]]> http://www.prweb.com/releases/2006/04/prweb366478.htm Huge NIMH Study of Antipsychotics—The Catie Trial—Was Compromised by Pharmaceutical Industry Input http://www.prweb.com/releases/2006/03/prweb352178.htm One of the largest studies ever conducted on antipsychotic medication—the CATIE Trial—was compromised by crucial input from the pharmaceutical industry, and the study’s results may not be valid as a result, according to The Carlat Psychiatry Report. (PRWeb Mar 1, 2006)

Read the full story at http://www.prweb.com/releases/2006/03/prweb352178.htm

]]> http://www.prweb.com/releases/2006/03/prweb352178.htm